Showing 651-660 of 21412 results for "".
- GLP-1 RAs and Substance Use Disorders: Findings from a Veteran Cohorthttps://reachmd.com/news/glp-1-ras-substance-use-disorder/2485984/In a large U.S. cohort of veterans with type 2 diabetes, initiation of GLP‑1 receptor agonists was associated with a lower risk of developing sev
- Study Shows liraglutide Results in Increased Insulin Sensitivity Independent of Weight Losshttps://reachmd.com/news/study-shows-liraglutide-results-in-increased-insulin-sensitivity-independent-of-weight-loss/2456767/by Jill Clendening A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type
- GLP‑1 RAs Plus Healthy Lifestyle Linked to Lower MACE Risk in T2Dhttps://reachmd.com/news/glp1-ras-plus-healthy-lifestyle-linked-to-lower-mace-risk-in-t2d/2485846/In adults with type 2 diabetes, an observational cohort analysis in which GLP‑1 receptor agonists use plus ad
- HER2 Amplification Extends Across Tumor Types, Highlighting New Opportunities for Precision Oncologyhttps://reachmd.com/news/her2-amplification-extends-across-tumor-types-highlighting-new-opportunities-for-precision-oncology/2486472/Key Takeaways HER2 amplification was identified in 5.7% of nearly 90,000 solid tumors in Japan, extending well be
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://reachmd.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Evaluating the Impact of Added Sugars in US Infant Formula on Baby Healthhttps://reachmd.com/news/evaluating-the-impact-of-added-sugars-in-us-infant-formula-on-baby-health/2471316/Assessing How Early Sugar Exposure Shapes Long-Term Health Outcomes This article explores concerns over high levels of added sugar in US infant formula, examining evidence that links early exposure to added sugars with an increased risk of obesity, type 2 diabetes,
- Streamlining Healthcare Technology and Patient Adherence: Addressing 504 Errors and Diabetic Retinopathy Screeninghttps://reachmd.com/news/streamlining-healthcare-technology-and-patient-adherence-addressing-504-errors-and-diabetic-retinopathy-screening/2471244/In the intersection of healthcare technology and patient care, understanding technical hurdles like 504 Gateway Time-out errors and improving patient adherence to screenings for conditions such as diabetic retinopathy can significantly influence outcomes.
- Diabetic Donor Kidneys: Five-Year Outcomes After Matchinghttps://reachmd.com/news/diabetic-donor-kidneys-five-year-outcomes-after-matching/2488715/Key Takeaways Among adult deceased-donor kidney recipients at a São Paulo transplant center, diabetic donors were older and more often hypertensive, and their recipients had lower unadjusted graft survival. Matched kidney-function and graft-survival differences by do
- Renal Clues at Diagnosis: Uncovering Kidney Risk in New-Onset Diabeteshttps://reachmd.com/news/renal-health-and-guideline-compliance-in-newly-diagnosed-diabetes-mellitus/2474259/When patients are first diagnosed with diabetes mellitus, the clinical lens often zooms in on blood glucose control. But a growing body of evidence suggests another vital parameter deserves early attention: renal health. Research now points to a high prevalence of
- New UH Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://reachmd.com/news/new-uh-study-targets-early-signs-of-vision-loss-in-diabetic-patients/2467853/A $3.3 million study at the University of Houston College of Optometry will track the health of patients with prediabetes and diabetes to find out who might develop eye problems and be at risk for future vision loss. The study is being led by Wendy Harrison, associate professor, and is under